IDEXX Laboratories is a diagnostics & research business based in the US. IDEXX Laboratories shares (IDXX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $477.67 – a decrease of 5.45% over the previous week. IDEXX Laboratories employs 11,000 staff and has a trailing 12-month revenue of around $3.8 billion.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $477.67 |
|---|---|
| 52-week range | $372.50 - $583.39 |
| 50-day moving average | $487.72 |
| 200-day moving average | $512.08 |
| Wall St. target price | $531.19 |
| PE ratio | 47.3879 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $10.08 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $477.67 from 2024-10-04
| 1 week (2024-10-01) | -3.58% |
|---|---|
| 1 month (2024-09-06) | 1.13% |
| 3 months (2024-07-08) | -1.25% |
| 6 months (2024-04-08) | -7.19% |
| 1 year (2023-10-06) | 7.11% |
|---|---|
| 2 years (2022-10-07) | 43.34% |
| 3 years (2021-10-08) | 617.02 |
| 5 years (2019-10-08) | 78.42% |
Valuing IDEXX Laboratories stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of IDEXX Laboratories's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
IDEXX Laboratories's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 47x. In other words, IDEXX Laboratories shares trade at around 47x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
IDEXX Laboratories's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 5.0279. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into IDEXX Laboratories's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
IDEXX Laboratories's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.3 billion.
The EBITDA is a measure of a IDEXX Laboratories's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $3.8 billion |
|---|---|
| Operating margin TTM | 32.41% |
| Gross profit TTM | $2 billion |
| Return on assets TTM | 22.77% |
| Return on equity TTM | 63.25% |
| Profit margin | 22.34% |
| Book value | $19.16 |
| Market Capitalization | $39.3 billion |
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like IDEXX Laboratories.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 29.79
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and IDEXX Laboratories's overall score of 29.79 (as at 12/31/2018) is nothing to write home about – landing it in it in the 55th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like IDEXX Laboratories is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 9.93/100
IDEXX Laboratories's environmental score of 9.93 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that IDEXX Laboratories is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 14.44/100
IDEXX Laboratories's social score of 14.44 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that IDEXX Laboratories is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 17.91/100
IDEXX Laboratories's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that IDEXX Laboratories is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
IDEXX Laboratories Inc was last rated for ESG on: 2019-01-01.
| Total ESG score | 29.79 |
|---|---|
| Total ESG percentile | 54.84 |
| Environmental score | 9.93 |
| Environmental score percentile | 6 |
| Social score | 14.44 |
| Social score percentile | 6 |
| Governance score | 17.91 |
| Governance score percentile | 6 |
We're not expecting IDEXX Laboratories to pay a dividend over the next 12 months.
IDEXX Laboratories's shares were split on a 2:1 basis on 15 June 2015. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your IDEXX Laboratories shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for IDEXX Laboratories shares which in turn could have impacted IDEXX Laboratories's share price.
Over the last 12 months, IDEXX Laboratories's shares have ranged in value from as little as $372.5 up to $583.39. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while IDEXX Laboratories's is 1.333. This would suggest that IDEXX Laboratories's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out the best-performing ETFs so far in 2024.